IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application Of:

Woulfe, et al.

Examiner:

Unknown

Serial No.: 10/728,420

Filed:

December 5, 2003

For:

ENGINEERED FAB' FRAGMENT

ANTI-TUMOR NECROSIS FACTOR)

ALPHA IN COMBINATION WITH

DISEASE MODIFYING

ANTI-RHEUMATIC DRUGS

CERTIFICATE OF MAILING

I hereby certify that this document is being deposited on this day with the U.S. Postal Service "Express Mail to Addressee" service under 37 C.F.R. 1.10 and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Mike Martin

Typed or Printed Name of Person Mailing Correspondence

EL 812640612 US

"Express Mail" Mailing Label Number

October 26, 2004 Mailing Date

Mail Stop Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

STATEMENT UNDER 37 C.F.R. 1.821 (f)

This is a response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed September 3, 2004.

Pursuant to 37 C.F.R. § 1.821(f), Applicants state that the Sequence Listing submitted in both paper copy and in the computer readable form are the same.

While no fees are due at this time, Applicants hereby authorize the Commissioner to charge any fees that may be required by this paper to Deposit Account 23-2426.

Respectfully submitted,

Date: 101. 26, 2004

Carol M. Nielsen

Reg. No. 37,676

Winstead Sechrest & Minick P.C. P.O. Box 50784
Dallas, Texas 75201
713-650-2722 phone
214-745-5390 fax
cnielsen@winstead.com

Attorney Docket No. 43407-P006US